The reduced burn rate and extended cash runway reduce near-term dilution risk. Upcoming data readouts in H1 2026 for TN-201 and TN-401 are key catalysts. The Alnylam deal validates platform but monetization is distant. Monitor insider selling trends despite positive operational progress.
Price Chart
Executive Summary
Tenaya Therapeutics reported financial results for Q4 and full year 2025, highlighted by reduced net loss and a strengthened cash position following a $55.8M financing. The company provided updates on its gene therapy programs TN-201 and TN-401, showing promising early clinical data, and advanced TN-301 with new preclinical data in DMD models. A multi-target collaboration with Alnylam brings up to $10M upfront and potential future milestones. Cash runway now extends into H2 2027.
Key Financial Metrics
Key Facts
- Net loss decreased to $20.2M in Q4 2025 from $23.8M in Q4 2024; full-year net loss fell to $90.6M from $111.1M in 2024.
- Cash, cash equivalents, and marketable securities totaled $100.5M as of December 31, 2025, up from $61.4M in 2024.
- Raised $55.8M net proceeds from a December 2025 public offering of 50M units (each consisting of one share and one warrant).
- Entered collaboration with Alnylam: up to $10M upfront and $1.1B in potential milestones.
- TN-201 and TN-401 showed generally well-tolerated safety profiles and early signs of efficacy in Phase 1b/2 trials.
- Preclinical data for TN-301 in DMD models showed functional improvements over givinostat.
Financial Impact
Cash increased by $39.1M year-over-year; R&D and G&A expenses declined significantly. Net loss improved by $20.5M year-over-year. $55.8M financing and $10M expected upfront from Alnylam extend cash runway into H2 2027.
Risk Factors
- Biotech clinical-stage risk: early data may not translate to later success.
- Dilution risk remains beyond 2027 if no additional funding or partnerships are secured.
- Upfront payment from Alnylam is 'up to' $10M — actual amount may be lower.
- Recent insider selling ($1.4M in 30 days) may signal lack of confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | DEFA14A | $0.4086 | awaiting T+60 | — | $0.4014 (−1.76%) |
Oct 23, 2026 4d ago | DEF 14A | $0.4086 | awaiting T+60 | — | $0.4014 (+1.76%) |
Aug 17, 2026 10w ago | 144 | $0.6990 | awaiting T+60 | — | $0.4014 (+42.58%) |
Jul 2, 2026 16w ago | 8-K | $0.7869 $0.5898 | ▼ −25.05% | ▼ −28.62% | $0.4014 (−48.99%) |
Jun 29, 2026 17w ago | 8-K | $0.7349 $0.6822 | ▼ −7.17% | ▼ −11.56% | $0.4014 (−45.38%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.7118 $0.6634 | ▲ +6.80% | ▲ +10.06% | $0.4014 (+43.61%) |
May 29, 2026 21w ago | 8-K | $0.8700 $0.7014 | ▼ −19.38% | ▼ −20.61% | $0.4014 (−53.86%) |
May 19, 2026 23w ago | Insider Cluster | $0.8080 $0.7281 | ▼ −9.89% | ▼ −14.89% | $0.4014 (−50.32%) |
Apr 16, 2026 27w ago | DEFA14A | $0.7470 $0.8365 | ▲ +11.98% | ▲ +4.94% | $0.4014 (−46.27%) |
Mar 11, 2026 32w ago | 8-K | $0.8930 $0.7280 | ▼ −18.48% | ▼ −29.17% | $0.4014 (−55.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers